BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Phase 3
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: Placebo
- First Posted Date
- 2003-11-21
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 903
- Registration Number
- NCT00073307
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
- First Posted Date
- 2003-06-02
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 56
- Registration Number
- NCT00059462
Repinotan in Patients With Acute Ischemic Stroke
Phase 2
Completed
- Conditions
- StrokeAcute Ischemic Stroke
- Interventions
- Drug: Placebo
- First Posted Date
- 2002-09-09
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 782
- Registration Number
- NCT00044915
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
Phase 2
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 137
- Registration Number
- NCT00044512
Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
Phase 2
Completed
- Conditions
- Breast NeoplasmsBreast Cancer, Metastatic
- Interventions
- Drug: BAY59-8862 (Cytotoxic Taxane)
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 82
- Registration Number
- NCT00044525
Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Drug: Taxane (Cytotoxic, BAY59-8862)
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 29
- Registration Number
- NCT00044551
Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: BAY59-8862 (Cytotoxic Taxane)
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2009-06-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 102
- Registration Number
- NCT00044538
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT00044564
Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen
Phase 3
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Bayer
- Registration Number
- NCT00002238
- Locations
- πΊπΈ
Alta Bates / Herrick Hosp, Berkeley, California, United States
πΊπΈUSC School of Medicine / Norris Cancer Hosp, Los Angeles, California, United States
πΊπΈCedars Sinai Med Ctr, Los Angeles, California, United States
Β© Copyright 2025. All Rights Reserved by MedPath